Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.91 USD
-0.04 (-1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.90 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ORGO 2.91 -0.04(-1.36%)
Will ORGO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ORGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORGO
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
ORGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
Best Momentum Stocks to Buy for January 5th
New Strong Buy Stocks for January 5th
Other News for ORGO
Lake Street starts Organogenesis with Buy on competitive advantages
Organogenesis initiated with bullish view at Lake Street
Organogenesis Shareholders Affirm Governance and Strategy
Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference